Literature DB >> 14515178

Lymphangiogenesis and tumor metastasis.

Riccardo E Nisato1, Jean-Christophe Tille, Michael S Pepper.   

Abstract

In several human cancers, increased expression in primary tumors of vascular endothelial growth factor-C (VEGF-C) is correlated with regional lymph node metastasis. Studies using transgenic mice overexpressing VEGF-C, or xenotransplantation of VEGF-C-expressing tumor cells into immunodeficient mice, have demonstrated a role for VEGF-C in tumor lymphangiogenesis and the subsequent formation of lymph node metastasis. However, at variance with data obtained in animal models, there is at present very little evidence for lymphangiogenesis in human tumors. Nonetheless, the striking correlation between levels of VEGF-C in primary human tumors and lymph node metastases exists, which suggests that VEGF-C may serve functions other than lymphangiogenesis. Thus, VEGF-C may activate pre-existing lymphatics which in turn become directly involved in tumor cell chemotaxis, intralymphatic intravasation and distal dissemination. A reciprocal dialogue is therefore likely to exist between tumor and lymphatic endothelial cells which results in the formation of lymph node metastases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14515178     DOI: 10.1160/TH03-04-0206

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

Review 1.  Pericytes: gatekeepers in tumour cell metastasis?

Authors:  Holger Gerhardt; Henrik Semb
Journal:  J Mol Med (Berl)       Date:  2007-09-22       Impact factor: 4.599

2.  Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer.

Authors:  Yutaka Yonemura; Yoshio Endo; Kayoko Tabata; Taiichi Kawamura; Hyo-Yung Yun; Etsurou Bandou; Takuma Sasaki; Masahiro Miura
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

3.  Clinical usefulness of D2-40 in non-small cell lung cancer.

Authors:  Kyung Hoon Min; Seoung Ju Park; Kyung Sun Lee; Sung Ho Hwang; So Ri Kim; Hee Moon; Hyo Jin Han; Myoung Ja Chung; Yong Chul Lee
Journal:  Lung       Date:  2010-11-25       Impact factor: 2.584

4.  Expression of vascular endothelial growth factor-C and the relationship between lymphangiogenesis and lymphatic metastasis in colorectal cancer.

Authors:  Yi-Tao Jia; Zhong-Xin Li; Yu-Tong He; Wei Liang; Hui-Chai Yang; Hong-Jun Ma
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

Review 5.  Lymphatic vessels in health and disease.

Authors:  Cristina T Kesler; Shan Liao; Lance L Munn; Timothy P Padera
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2012-12-03

Review 6.  [Invasion patterns and metastasis of urothelial carcinoma. A challenge for translational research].

Authors:  C Bolenz; T Martini; M S Michel
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

Review 7.  Molecular and functional diversity of vascular endothelial growth factors.

Authors:  Yasuo Yamazaki; Takashi Morita
Journal:  Mol Divers       Date:  2006-11       Impact factor: 3.364

8.  Clinicopathological Significance of VEGF-C, VEGFR-3 and Cyclooxygenase-2 in Early-Stage Cervical Cancer.

Authors:  Xiaoyan Shi; Ling Xi; Danhui Weng; Gang Chen; Xiaohong Song; Peng Wu; Beibei Wang; Juncheng Wei; Shixuan Wang; Jianfeng Zhou; Ding Ma
Journal:  Int J Biomed Sci       Date:  2008-03

9.  Expression of angiopoietin-2 and vascular endothelial growth factor receptor-3 correlates with lymphangiogenesis and angiogenesis and affects survival of oral squamous cell carcinoma.

Authors:  Chao Li; Jinchuan Fan; Xicheng Song; Bing Zhang; Yu Chen; Chunhua Li; Kun Mi; Hong Ma; Yufeng Song; Xiaofeng Tao; Guojun Li
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

10.  Lymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosis.

Authors:  Vanessa F Z Marinho; Konradin Metze; Fernanda S F Sanches; Gislene F S Rocha; Helenice Gobbi
Journal:  BMC Cancer       Date:  2008-02-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.